• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹泻型肠易激综合征患者报告结局症状测量的定性研究。

Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome.

机构信息

TwoLegs Consulting, Newton, Massachusetts, USA.

Pharmerit International, Cambridge, Massachusetts, USA.

出版信息

Clin Transl Gastroenterol. 2014 Jun 26;5(6):e59. doi: 10.1038/ctg.2014.7.

DOI:10.1038/ctg.2014.7
PMID:24964994
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4077041/
Abstract

OBJECTIVES

Despite a documented clinical need, no patient reported outcome (PRO) symptom measure meeting current regulatory requirements for clinically relevant end points is available for the evaluation of treatment benefit in diarrhea-predominant IBS (IBS-D).

METHODS

Patients (N=113) with IBS-D participated in five study phases: (1) eight concept elicitation focus groups (N=34), from which a 17-item IBS-D Daily Symptom Diary and four-item IBS-D Symptom Event Log (Diary and Event Log) were developed; (2) one-on-one cognitive interviews (N=11) to assess the instrument's comprehensiveness, understandability, appropriateness, and readability; (3) four data triangulation focus groups (N=32) to confirm the concepts elicited; (4) two hybrid (concept elicitation and cognitive interview) focus groups (N=16); and (5) two iterative sets of one-on-one cognitive interviews (N=20) to further clarify the symptoms of IBS-D and debrief a revised seven-item Diary and four-item Event Log.

RESULTS

Of thirty-six concepts initially identified, 22 were excluded because they were not saturated, not clinically relevant, not critical symptoms of IBS-D, considered upper GI symptoms, or too broad or vaguely defined. The remaining concepts were diarrhea, immediate need (urgency), bloating/pressure, frequency of bowel movements, cramps, abdominal/stomach pain, gas, completely emptied bowels/incomplete evacuation, accidents, bubbling in intestines (bowel sounds), rectal burning, stool consistency, rectal spasm, and pain while wiping. The final instrument included a daily diary with separate items for abdominal and stomach pain and an event log with four items completed after each bowel movement as follows: (1) a record of the bowel movement/event and an assessment of (2) severity of immediacy of need/bowel urgency, (3) incomplete evacuation, and (4) stool consistency (evaluated using the newly developed Astellas Stool Form Scale). Based on rounds of interviews and clinical input, items considered secondary or nonspecific to IBS-D (rectal burning, bubbling in intestines, spasms, and pain while wiping) were excluded.

CONCLUSIONS

The IBS-D Symptom Diary and Event Log represent a rigorously developed PRO instrument for the measurement of the IBS-D symptom experience from the perspective of the patient. Its content validity has been supported, and future work should evaluate the instrument's psychometric properties.

摘要

目的

尽管有临床文献记录表明存在需求,但目前尚无满足临床相关终点标准的可用于评估腹泻型肠易激综合征(IBS-D)治疗获益的患者报告结局(PRO)症状测量工具。

方法

113 例 IBS-D 患者参与了五个研究阶段:(1)8 个概念发掘焦点小组(n=34),由此开发了 17 项 IBS-D 日常症状日记和 4 项 IBS-D 症状事件日志(日记和事件日志);(2)一对一认知访谈(n=11),以评估工具的全面性、可理解性、适当性和可读性;(3)4 个数据三角焦点小组(n=32),以确认所引出的概念;(4)2 个混合(概念发掘和认知访谈)焦点小组(n=16);以及(5)2 组迭代一对一认知访谈(n=20),以进一步阐明 IBS-D 的症状并讨论修订后的 7 项日记和 4 项事件日志。

结果

最初确定的 36 个概念中有 22 个被排除,因为它们未达到饱和、与临床不相关、不是 IBS-D 的关键症状、被认为是上消化道症状、过于广泛或定义模糊。其余概念包括腹泻、立即需求(紧迫性)、腹胀/压迫感、排便频率、痉挛、腹部/胃部疼痛、气体、完全排空肠道/不完全排空、意外、肠道中冒泡(肠鸣音)、直肠烧灼感、粪便稠度、直肠痉挛和擦拭时疼痛。最终的工具包括一个带有单独的腹部和胃部疼痛项目的日常日记和一个在每次排便后完成的四个项目的事件日志,具体如下:(1)记录排便/事件,并评估(2)急迫性/紧迫性、(3)不完全排空和(4)粪便稠度的严重程度(使用新开发的 Astellas 粪便形态量表评估)。基于几轮访谈和临床意见,排除了被认为是次要的或与 IBS-D 无关的项目(直肠烧灼感、肠道中冒泡、痉挛和擦拭时疼痛)。

结论

IBS-D 症状日记和事件日志代表了一种经过严格开发的 PRO 工具,可从患者角度测量 IBS-D 的症状体验。其内容效度已得到支持,未来的工作应评估该工具的心理测量特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/64074e6afe06/ctg20147f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/9065dcec0f5f/ctg20147f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/6b8c7d22d270/ctg20147f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/64074e6afe06/ctg20147f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/9065dcec0f5f/ctg20147f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/6b8c7d22d270/ctg20147f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad88/4077041/64074e6afe06/ctg20147f3.jpg

相似文献

1
Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征患者报告结局症状测量的定性研究。
Clin Transl Gastroenterol. 2014 Jun 26;5(6):e59. doi: 10.1038/ctg.2014.7.
2
Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population.在临床研究人群中对一种新开发的用于腹泻型肠易激综合征的患者报告结局工具进行评估及性能测试。
Therap Adv Gastroenterol. 2017 Sep;10(9):673-687. doi: 10.1177/1756283X17726018. Epub 2017 Aug 24.
3
Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log.肠易激综合征腹泻型每日症状日记和症状事件日志的心理测量评估。
Qual Life Res. 2016 Dec;25(12):3197-3208. doi: 10.1007/s11136-016-1335-1. Epub 2016 Jun 24.
4
Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.用于评估临床试验中治疗效果的肠易激综合征症状日记的开发:基础定性研究。
Value Health. 2017 Apr;20(4):618-626. doi: 10.1016/j.jval.2016.11.001. Epub 2017 Jan 3.
5
Psychometric Evaluation of the Diary for Irritable Bowel Syndrome Symptoms-Constipation in a Prospective Observational Study.前瞻性观察研究中便秘型肠易激综合征症状日记的心理测量评估。
Value Health. 2024 May;27(5):614-622. doi: 10.1016/j.jval.2024.01.013. Epub 2024 Feb 2.
6
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.美沙拉嗪治疗腹泻型肠易激综合征(IBS-D)的疗效和作用机制:一项随机对照试验的研究方案。
Trials. 2013 Jan 9;14:10. doi: 10.1186/1745-6215-14-10.
7
Diarrhea-predominant irritable bowel syndrome: creation of an electronic version of a patient-reported outcome instrument by conversion from a pen-and-paper version and evaluation of their equivalence.腹泻型肠易激综合征:通过将纸质版转换为电子版来创建患者报告结局工具,并评估二者的等效性。
Patient Relat Outcome Meas. 2017 Jul 18;8:83-95. doi: 10.2147/PROM.S126605. eCollection 2017.
8
IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment.IBS 患者的粪便常呈现稀便与硬便/团块便之间的频繁波动:对治疗的启示。
Am J Gastroenterol. 2012 Feb;107(2):286-95. doi: 10.1038/ajg.2011.358. Epub 2011 Nov 8.
9
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.在一项 2 期研究中,Eluxadoline 使腹泻型肠易激综合征患者受益。
Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.
10
Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study.一种氨基酸饮料配方对腹泻型肠易激综合征的有效性:一项实用的真实世界研究。
World J Gastrointest Pharmacol Ther. 2023 Dec 12;14(5):39-49. doi: 10.4292/wjgpt.v14.i5.39.

引用本文的文献

1
Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population.在临床研究人群中对一种新开发的用于腹泻型肠易激综合征的患者报告结局工具进行评估及性能测试。
Therap Adv Gastroenterol. 2017 Sep;10(9):673-687. doi: 10.1177/1756283X17726018. Epub 2017 Aug 24.
2
Diarrhea-predominant irritable bowel syndrome: creation of an electronic version of a patient-reported outcome instrument by conversion from a pen-and-paper version and evaluation of their equivalence.腹泻型肠易激综合征:通过将纸质版转换为电子版来创建患者报告结局工具,并评估二者的等效性。
Patient Relat Outcome Meas. 2017 Jul 18;8:83-95. doi: 10.2147/PROM.S126605. eCollection 2017.
3

本文引用的文献

1
Severity in irritable bowel syndrome: a Rome Foundation Working Team report.肠易激综合征的严重程度:罗马基金会工作组报告。
Am J Gastroenterol. 2011 Oct;106(10):1749-59; quiz 1760. doi: 10.1038/ajg.2011.201. Epub 2011 Jul 12.
2
Asian consensus on irritable bowel syndrome.亚洲肠易激综合征共识。
J Gastroenterol Hepatol. 2010 Jul;25(7):1189-205. doi: 10.1111/j.1440-1746.2010.06353.x.
3
Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research.评估并展示定性研究中支持患者报告结局研究的数据饱和情况。
Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.雷莫司琼的随机、安慰剂对照、IV期试点研究,以评估腹泻型肠易激综合征男性患者的共同主要终点。
Biopsychosoc Med. 2017 Mar 16;11:8. doi: 10.1186/s13030-017-0093-9. eCollection 2017.
4
Regulating effect of TongXie-YaoFang on colonic epithelial secretion Cl and HCO channel.痛泻要方对结肠上皮分泌Cl和HCO通道的调节作用
World J Gastroenterol. 2016 Dec 28;22(48):10584-10591. doi: 10.3748/wjg.v22.i48.10584.
5
[Patient perspective of pain assessment by nursing personnel : Qualitative cross-sectional study on use of the NRS].[患者对护理人员疼痛评估的看法:关于使用数字评分量表的定性横断面研究]
Schmerz. 2017 Apr;31(2):123-130. doi: 10.1007/s00482-016-0181-y.
6
Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log.肠易激综合征腹泻型每日症状日记和症状事件日志的心理测量评估。
Qual Life Res. 2016 Dec;25(12):3197-3208. doi: 10.1007/s11136-016-1335-1. Epub 2016 Jun 24.
7
Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.临床结局评估:概念基础——国际药物经济学与结果研究协会(ISPOR)临床结局评估——结果研究新兴良好实践特别工作组报告
Value Health. 2015 Sep;18(6):741-52. doi: 10.1016/j.jval.2015.08.006. Epub 2015 Aug 24.
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):269-81. doi: 10.1586/erp.10.30.
4
PRO development: rigorous qualitative research as the crucial foundation.专业发展:严谨的定性研究是关键基础。
Qual Life Res. 2010 Oct;19(8):1087-96. doi: 10.1007/s11136-010-9677-6. Epub 2010 May 30.
5
Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners.肠易激综合征:流行病学、诊断与治疗——临床医生更新知识
J Gastroenterol Hepatol. 2010 Apr;25(4):691-9. doi: 10.1111/j.1440-1746.2009.06120.x. Epub 2010 Jan 13.
6
Covert assessment of concurrent and construct validity of a chart to characterize fecal output and diarrhea in patients receiving enteral nutrition.对一份用于描述接受肠内营养患者粪便排出量和腹泻情况的图表进行同时效度和结构效度的隐性评估。
JPEN J Parenter Enteral Nutr. 2008 Mar-Apr;32(2):160-8. doi: 10.1177/0148607108314769.
7
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.定性研究报告的统一标准(COREQ):访谈和焦点小组的32项清单
Int J Qual Health Care. 2007 Dec;19(6):349-57. doi: 10.1093/intqhc/mzm042. Epub 2007 Sep 14.
8
Functional bowel disorders.功能性肠病
Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061.
9
Performance of the EQ-5D in patients with irritable bowel syndrome.EQ-5D在肠易激综合征患者中的表现。
Value Health. 2006 Mar-Apr;9(2):90-7. doi: 10.1111/j.1524-4733.2006.00086.x.
10
Health Insurance Portability and Accountability Act of 1996. Public Law 104-191.1996年《健康保险流通与责任法案》。公法第104 - 191号。
US Statut Large. 1996 Aug 21;110:1936-2103.